Posted by Michael Wonder on 07 Jul 2026
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
25 June 2026 - Eli Lilly today announced additional details regarding the Medicare GLP-1 Bridge program taking effect 1 July 2026.
Under the program, Medicare Part D patients may be able to access Foundayo (orforglipron) or Zepbound (tirzepatide) KwikPen for single patient use for weight management.
The Medicare GLP-1 Bridge program will be the first time eligible Medicare Part D patients will be able to broadly receive coverage for a GLP-1 for overweight or obesity.1 We believe this is a milestone that reflects growing recognition of the impact of obesity, including in older adults.
